VanEck Associates’s Novartis NVS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $99.3M | Sell |
633,523
-258,280
| -29% | -$38.7M | 0.06% | 180 |
|
|
2026
Q1 | $136M | Sell |
891,803
-68,854
| -7% | -$10.6M | 0.1% | 159 |
|
|
2025
Q4 | $132M | Buy |
960,657
+515,999
| +116% | +$67.6M | 0.11% | 152 |
|
|
2025
Q3 | $57M | Buy |
444,658
+45,173
| +11% | +$5.51M | 0.05% | 209 |
|
|
2025
Q2 | $48.3M | Buy |
399,485
+76,106
| +24% | +$8.58M | 0.05% | 209 |
|
|
2025
Q1 | $36M | Sell |
323,379
-4,235
| -1% | -$451K | 0.05% | 232 |
|
|
2024
Q4 | $31.9M | Buy |
327,614
+16,901
| +5% | +$1.8M | 0.04% | 242 |
|
|
2024
Q3 | $35.4M | Buy |
310,713
+24,123
| +8% | +$2.74M | 0.04% | 221 |
|
|
2024
Q2 | $30.5M | Buy |
286,590
+16,150
| +6% | +$1.62M | 0.04% | 215 |
|
|
2024
Q1 | $26.2M | Buy |
270,440
+55,142
| +26% | +$5.65M | 0.04% | 233 |
|
|
2023
Q4 | $21.7M | Sell |
215,298
-4,811
| -2% | -$464K | 0.04% | 229 |
|
|
2023
Q3 | $22.4M | Buy |
220,109
+29,252
| +15% | +$2.97M | 0.05% | 221 |
|
|
2023
Q2 | $19.3M | Sell |
190,857
-23,920
| -11% | -$2.39M | 0.04% | 250 |
|
|
2023
Q1 | $19.8M | Sell |
214,777
-102,878
| -32% | -$8.98M | 0.05% | 241 |
|
|
2022
Q4 | $28.8M | Sell |
317,655
-22,560
| -7% | -$1.9M | 0.07% | 197 |
|
|
2022
Q3 | $25.9M | Sell |
340,215
-2,989
| -0.9% | -$248K | 0.08% | 193 |
|
|
2022
Q2 | $29M | Buy |
343,204
+123,649
| +56% | +$10.8M | 0.08% | 203 |
|
|
2022
Q1 | $19.3M | Buy |
219,555
+1,900
| +0.9% | +$165K | 0.04% | 255 |
|
|
2021
Q4 | $19M | Buy |
217,655
+27,874
| +15% | +$2.31M | 0.04% | 261 |
|
|
2021
Q3 | $15.5M | Buy |
189,781
+61,671
| +48% | +$5.55M | 0.04% | 286 |
|
|
2021
Q2 | $11.7M | Sell |
128,110
-9,498
| -7% | -$846K | 0.03% | 324 |
|
|
2021
Q1 | $11.8M | Buy |
137,608
+135
| +0.1% | +$12.1K | 0.03% | 311 |
|
|
2020
Q4 | $13M | Buy |
137,473
+3,567
| +3% | +$312K | 0.04% | 264 |
|
|
2020
Q3 | $11.6M | Sell |
133,906
-148
| -0.1% | -$12.8K | 0.04% | 243 |
|
|
2020
Q2 | $11.7M | Buy |
134,054
+20,817
| +18% | +$1.8M | 0.04% | 236 |
|
|
2020
Q1 | $9.34M | Buy |
113,237
+7,031
| +7% | +$627K | 0.05% | 230 |
|
|
2019
Q4 | $10.1M | Buy |
106,206
+25,077
| +31% | +$2.25M | 0.04% | 259 |
|
|
2019
Q3 | $7.05M | Sell |
81,129
-15,427
| -16% | -$1.39M | 0.03% | 278 |
|
|
2019
Q2 | $8.82M | Sell |
96,556
-19,149
| -17% | -$1.62M | 0.04% | 239 |
|
|
2019
Q1 | $9.97M | Sell |
115,705
-42,139
| -27% | -$3.38M | 0.05% | 215 |
|
|
2018
Q4 | $12.1M | Sell |
157,844
-20,371
| -11% | -$1.59M | 0.06% | 211 |
|
|
2018
Q3 | $13.8M | Sell |
178,215
-28,986
| -14% | -$2.14M | 0.07% | 216 |
|
|
2018
Q2 | $14M | Buy |
207,201
+36,459
| +21% | +$2.52M | 0.07% | 208 |
|
|
2018
Q1 | $12.4M | Sell |
170,742
-9,863
| -5% | -$751K | 0.06% | 220 |
|
|
2017
Q4 | $13.6M | Sell |
180,605
-2,230
| -1% | -$168K | 0.07% | 210 |
|
|
2017
Q3 | $14.1M | Sell |
182,835
-58,531
| -24% | -$4.42M | 0.07% | 209 |
|
|
2017
Q2 | $18.1M | Sell |
241,366
-52,662
| -18% | -$3.73M | 0.1% | 163 |
|
|
2017
Q1 | $19.6M | Sell |
294,028
-22,731
| -7% | -$1.51M | 0.09% | 169 |
|
|
2016
Q4 | $20.7M | Buy |
316,759
+150,604
| +91% | +$9.77M | 0.1% | 149 |
|
|
2016
Q3 | $11.8M | Sell |
166,155
-14,923
| -8% | -$1.09M | 0.05% | 191 |
|
|
2016
Q2 | $13.4M | Sell |
181,078
-18,597
| -9% | -$1.28M | 0.07% | 170 |
|
|
2016
Q1 | $13M | Sell |
199,675
-137,615
| -41% | -$9.36M | 0.09% | 150 |
|
|
2015
Q4 | $26M | Buy |
337,290
+35,603
| +12% | +$2.83M | 0.21% | 113 |
|
|
2015
Q3 | $24.8M | Sell |
301,687
-27,568
| -8% | -$2.45M | 0.19% | 117 |
|
|
2015
Q2 | $29M | Sell |
329,255
-28,040
| -8% | -$2.57M | 0.17% | 125 |
|
|
2015
Q1 | $31.6M | Buy |
357,295
+4,698
| +1% | +$417K | 0.18% | 117 |
|
|
2014
Q4 | $29.3M | Sell |
352,597
-127,714
| -27% | -$10.6M | 0.18% | 117 |
|
|
2014
Q3 | $40.5M | Buy |
480,311
+51,182
| +12% | +$4.14M | 0.21% | 113 |
|
|
2014
Q2 | $34.8M | Buy |
429,129
+66,575
| +18% | +$5.24M | 0.16% | 125 |
|
|
2014
Q1 | $27.6M | Buy |
362,554
+80,834
| +29% | +$5.89M | 0.14% | 123 |
|
|
2013
Q4 | $20.3M | Buy |
281,720
+6,252
| +2% | +$435K | 0.1% | 136 |
|
|
2013
Q3 | $18.9M | Sell |
275,468
-12,932
| -4% | -$856K | 0.1% | 115 |
|
|
2013
Q2 | $18.3M | Buy |
+288,400
| New | +$18.8M | 0.1% | 112 |
|
Other funds holding NVS
VanEck Associates's NVS Position: Q2 2026 in Review
VanEck Associates reduced its Novartis (NVS) stake by 29% in Q2 2026, selling an estimated $38.7M and leaving 633,523 shares worth $99.3M. The position accounts for 0.06% of the portfolio, ranked #180.
VanEck Associates first reported a position in NVS in Q2 2013 and has held it in 53 quarters since. The position peaked at $136M in Q1 2026. 1,617 funds tracked by Wall St. Rank hold NVS as of Q2 2026.
- VanEck Associates held 633,523 shares of Novartis worth $99.3M as of Q2 2026.
- VanEck Associates sold 258,280 Novartis shares in Q2 2026, an estimated $38.7M.
- Novartis made up 0.06% of VanEck Associates's portfolio in Q2 2026, its #180 holding.
- VanEck Associates first reported a position in Novartis in Q2 2013 and has held it in 53 quarters since.
- VanEck Associates's Novartis position peaked at $136M in Q1 2026.
- 1,617 funds tracked by Wall St. Rank held Novartis as of Q2 2026.
Based on VanEck Associates's 13F filing for Q2 2026, filed 14 Aug 2026.